keyword
MENU ▼
Read by QxMD icon Read
search

Targeted therapies for bladder cancer

keyword
https://www.readbyqxmd.com/read/27904673/microrna-206-acts-as-a-tumor-suppressor-in-bladder-cancer-via-targeting-yrdc
#1
Bisheng Huang, Wei Zhai, Guanghui Hu, Chi Huang, Tiancheng Xie, Jingwei Zhang, Yunfei Xu
Accumulating evidence suggested that microRNA (miRNA) plays important regulatory roles in the initiation and development of various cancers. Previous study showed that microRNA-206 (miR-206) is dysregulated in human bladder cancer tissues, however, the biological function and underlying mechanisms of miR-206 in human bladder cancer remain unknown. In the present study, we aimed to investigate the clinical significance of miR-206 and its target gene YRDC in human bladder cancer, and to determine its effects on oncogenic phenotypes of this disease...
2016: American Journal of Translational Research
https://www.readbyqxmd.com/read/27895683/salvage-interstitial-brachytherapy-based-on-computed-tomography-for-recurrent-cervical-cancer-after-radical-hysterectomy-and-adjuvant-radiation-therapy-case-presentations-and-introduction-of-the-technique
#2
Zhong-Shan Liu, Jie Guo, Yang-Zhi Zhao, Xia Lin, Bin Chen, Ming Zhang, Jiang-Ming Li, Xiao-Jun Ren, Bing-Ya Zhang, Tie-Jun Wang
PURPOSE: Locally recurring cervical cancer after surgery and adjuvant radiotherapy remains a major therapeutic challenge. This paper presents a new therapeutic technique for such patients: interstitial brachytherapy (BT) guided by real-time three-dimensional (3D) computed tomography (CT). MATERIAL AND METHODS: Sixteen patients with recurrent cervical cancer after radical surgery and adjuvant external-beam radiotherapy (EBRT) were included in this study. These patients underwent high-dose-rate (HDR) interstitial BT with free-hand placement of metal needles guided by real-time 3D-CT...
October 2016: Journal of Contemporary Brachytherapy
https://www.readbyqxmd.com/read/27893422/pttg1-regulated-by-mir-146-3p-promotes-bladder-cancer-migration-invasion-metastasis-and-growth
#3
Wei Xiang, Xinchao Wu, Chao Huang, Miao Wang, Xian Zhao, Gang Luo, Yawei Li, Guosong Jiang, Xingyuan Xiao, Fuqing Zeng
Pituitary tumor-transforming gene 1 (PTTG1) is identified as an oncogene, and overexpresses in many tumors. However, the role of PTTG1 in bladder cancer (BC) hasn't yet been characterized well. In this study, we showed the expression of PTTG1 mRNA and protein were both significantly increased in BC tissues and cells. The PTTG1 protein levels were positive correlated with increased tumor size, tumor-node-metastasis (TNM) stage, lymphatic invasion and distant metastasis of BC. PTTG1 knockdown dramatically suppressed the migration, invasion, metastasis and growth, and induced senescence and cell-cycle arrest at G0/G1 phase of BC cells...
November 22, 2016: Oncotarget
https://www.readbyqxmd.com/read/27872478/circulating-tumour-cells-as-biomarkers-of-prostate-bladder-and-kidney-cancer
#4
REVIEW
Michael A Gorin, James E Verdone, Emma van der Toom, Trinity J Bivalacqua, Mohamad E Allaf, Kenneth J Pienta
Circulating tumour cells (CTCs) have been studied as biomarkers of a number of solid malignancies. Potential clinical applications for CTC analysis include early cancer detection, disease staging, monitoring for recurrence, prognostication, and to aid in the selection of therapy. In the field of urologic oncology, CTCs have been most widely studied as prognostic biomarkers of castration-resistant prostate cancer. Additionally, emerging data support a role for CTCs to help identify which patients are most likely to respond to novel androgen-pathway targeted therapies, such as abiraterone and enzalutamide...
November 22, 2016: Nature Reviews. Urology
https://www.readbyqxmd.com/read/27867173/evaluation-of-in-vivo-volumetric-dosimetry-for-prostate-cancer-using-electronic-portal-imaging-device
#5
Toshikazu Imae, Shigeharu Takenaka, Yuuichi Watanabe, Yukari Okano, Makoto Nedu, Shigeki Saegusa, Yukihiro Takeuchi, Keiichi Yano, Akihiro Haga, Kenshirou Shiraishi, Hideomi Yamashita, Keiichi Nakagawa
PURPOSE: Volumetric modulated arc therapy (VMAT) is capable of acquiring projection images using electronic portal imaging device (EPID). Commercial EPID-based dosimetry software, dosimetry check (DC), allows in vivo dosimetry using projection images. The purpose of this study was to evaluate in vivo dosimetry for prostate cancer using VMAT. METHOD: VMAT plans were generated for eight patients with prostate cancer using treatment planning system (TPS), and patient quality assurances (QAs) were carried out with phantom...
2016: Nihon Hoshasen Gijutsu Gakkai Zasshi
https://www.readbyqxmd.com/read/27866896/performance-of-the-irregular-surface-compensator-compared-with-four-field-box-and-intensity-modulated-radiation-therapy-for-gynecologic-cancer
#6
Wonmo Sung, Jung-In Kim, Hyun Suk Kim, Hak Jae Kim, Yang Hoon Lee, Sung-Joon Ye
PURPOSE: A retrospective planning study was undertaken to evaluate the dosimetric advantages of the irregular surface compensator (ISC) technique, a forward planning technique with electronic compensation algorithm available on Varian Eclipse treatment planning system. This was extensively compared to the conventional four-field box (4FB) and intensity modulated radiation therapy using 5 fields (IMRT5F) on gynecologic cancer patients. METHODS: Twenty-two patients were enrolled...
November 17, 2016: Physica Medica: PM
https://www.readbyqxmd.com/read/27846884/future-perspectives-in-melanoma-research-meeting-report-from-the-melanoma-bridge-napoli-december-1st-4th-2015
#7
Paolo A Ascierto, Sanjiv Agarwala, Gerardo Botti, Alessandra Cesano, Gennaro Ciliberto, Michael A Davies, Sandra Demaria, Reinhard Dummer, Alexander M Eggermont, Soldano Ferrone, Yang Xin Fu, Thomas F Gajewski, Claus Garbe, Veronica Huber, Samir Khleif, Michael Krauthammer, Roger S Lo, Giuseppe Masucci, Giuseppe Palmieri, Michael Postow, Igor Puzanov, Ann Silk, Stefani Spranger, David F Stroncek, Ahmad Tarhini, Janis M Taube, Alessandro Testori, Ena Wang, Jennifer A Wargo, Cassian Yee, Hassane Zarour, Laurence Zitvogel, Bernard A Fox, Nicola Mozzillo, Francesco M Marincola, Magdalena Thurin
The sixth "Melanoma Bridge Meeting" took place in Naples, Italy, December 1st-4th, 2015. The four sessions at this meeting were focused on: (1) molecular and immune advances; (2) combination therapies; (3) news in immunotherapy; and 4) tumor microenvironment and biomarkers. Recent advances in tumor biology and immunology has led to the development of new targeted and immunotherapeutic agents that prolong progression-free survival (PFS) and overall survival (OS) of cancer patients. Immunotherapies in particular have emerged as highly successful approaches to treat patients with cancer including melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), bladder cancer, and Hodgkin's disease...
November 15, 2016: Journal of Translational Medicine
https://www.readbyqxmd.com/read/27836246/emerging-role-of-immunotherapy-in-urothelial-carcinoma-immunobiology-biomarkers
#8
REVIEW
Randy F Sweis, Matthew D Galsky
Urothelial bladder cancer is one of the first cancers recognized to be immunogenic since 40 years ago when the use of bacillus Calmette-Guerin was shown to prevent recurrence. Since that time, our knowledge of immune biology of cancer has expanded tremendously, and patients with bladder cancer finally have new active immunotherapeutic drugs on the horizon. Anti-programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) therapy has shown impressively durable responses in urothelial bladder cancer (UBC), but the reported response rates warrant improvement...
December 2016: Urologic Oncology
https://www.readbyqxmd.com/read/27831653/a-study-of-ccnd1-with-epithelial-ovarian-cancer-cell-proliferation-and-apoptosis
#9
J Dai, R-J Wei, R Li, J-B Feng, Y-L Yu, P-S Liu
OBJECTIVE: Ovarian cancer is a gynecological malignancy with high mortality rates all over the world. Markers for diagnosis, prognosis and therapy are urgently required to improve the mortality rates. As a key proto-oncogene, CCND1 is known to be amplified in many different carcinomas, including breast cancer, esophageal cancer, bladder cancer, endometrial cancer and ovarian cancer, etc. CCND1 plays an important role in cancer development and progression. However, its function and mechanism have not been completely elucidated in ovarian cancer...
October 2016: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/27823983/genomic-profiling-is-predictive-of-response-to-cisplatin-treatment-but-not-to-pi3k-inhibition-in-bladder-cancer-patient-derived-xenografts
#10
Lei Wei, Sreenivasulu Chintala, Eric Ciamporcero, Swathi Ramakrishnan, May Elbanna, Jianmin Wang, Qiang Hu, Sean T Glenn, Mitsuko Murakami, Lu Liu, Eduardo Cortes Gomez, Yuchen Sun, Jacob Conroy, Kiersten Marie Miles, Kullappan Malathi, Sudha Ramaiah, Anand Anbarasu, Anna Woloszynska-Read, Candace S Johnson, Jeffrey Conroy, Song Liu, Carl D Morrison, Roberto Pili
PURPOSE: Effective systemic therapeutic options are limited for bladder cancer. In this preclinical study we tested whether bladder cancer gene alterations may be predictive of treatment response. EXPERIMENTAL DESIGN: We performed genomic profiling of two bladder cancer patient derived tumor xenografts (PDX). We optimized the exome sequence analysis method to overcome the mouse genome interference. RESULTS: We identified a number of somatic mutations, mostly shared by the primary tumors and PDX...
November 3, 2016: Oncotarget
https://www.readbyqxmd.com/read/27823620/immunomodulatory-proteins-fip-gts-and-chloroquine-induce-caspase-independent-cell-death-via-autophagy-for-resensitizing-cisplatin-resistant-urothelial-cancer-cells
#11
I-Lun Hsin, Shao-Chuan Wang, Jian-Ri Li, Tsai-Chun Ciou, Chih-Hsien Wu, Hung-Ming Wu, Jiunn-Liang Ko
BACKGROUND: Chloroquine, a lysosomal inhibitor, is used for malaria, rheumatoid arthritis, and lupus erythematosus therapy. In our previous study, FIP-gts, an immunomodulatory protein from Ganoderma tsugae, inhibited cell viability in lung cancer cells and urothelial cancer cells. Urothelial carcinoma is the most common type of bladder cancer. Cisplatin resistance is an important issue in urothelial carcinoma therapy. PURPOSE: The aim of this study is to investigate the effect of combination treatment with FIP-gts and chloroquine on cytotoxicity to resensitize the cisplatin-resistant cells...
December 1, 2016: Phytomedicine: International Journal of Phytotherapy and Phytopharmacology
https://www.readbyqxmd.com/read/27816539/feasibility-study-of-toxicity-outcomes-using-gec-estro-contouring-guidelines-on-ct-based-instead-of-mri-based-planning-in-locally-advanced-cervical-cancer-patients
#12
Vicky Koh, Bok Ai Choo, Khai Mun Lee, Teng Hwee Tan, Jen Hui Jeffrey Low, Soon Yau Joseph Ng, Arunachalam Ilancheran, Liang Shen, Johann Tang
PURPOSE: To report late rectal and bladder toxicity outcomes of a CT-based image-guided brachytherapy (IGBT) technique for treatment of cervical cancer. METHODS AND MATERIALS: Between 2008 and 2014, 95 women with International Federation of Gynecology and Obstetrics stage IB to IVA cervical carcinoma treated with definitive concurrent cisplatin-based chemotherapy and external beam radiation therapy 50.4 Gy in 28 fractions followed by planned prescription dose of 7 Gy × 4 fractions of high-dose-rate IGBT was retrospectively reviewed...
November 2, 2016: Brachytherapy
https://www.readbyqxmd.com/read/27812861/metastatic-bladder-cancer-second-line-treatment-and-recommendations-of-the-genitourinary-tumor-division-of-the-galician-oncologic-society-sog-gu
#13
REVIEW
Jorge García, Lucia Santomé, Urbano Anido, Ovidio Fernández-Calvo, Javier Afonso-Afonso, Martín Lázaro, Ana Medina, Sergio Vázquez Estévez
Once metastatic bladder cancer has progressed to first-line treatment, the number of therapeutic options is scarce. Among chemotherapeutic agents showing activity in phase II trials, including taxanes, vinflunine (VFL) is the only one shown to increase overall survival in a phase III trial. In addition to its efficacy, VFL is safe in special population groups. Despite this, the prognosis for these patients remains poor, and more effective therapies need to be developed. Agents acting on new therapeutic targets as well as biomarkers to aid matching patients to specific treatments are currently under evaluation...
December 2016: Current Oncology Reports
https://www.readbyqxmd.com/read/27790072/dosimetric-influence-of-photon-beam-energy-and-number-of-arcs-on-volumetric-modulated-arc-therapy-in-carcinoma-cervix-a-planning-study
#14
Girigesh Yadav, Manindra Bhushan, Abhinav Dewan, Upasna Saxena, Lalit Kumar, Deepika Chauhan, Kothanda Raman, Swarupa Mitra, Mahammood Suhail
AIM: Aim of the present study was to compare the dosimetric impact of different photon beam energies and number of arcs in the treatment of carcinoma cervix. BACKGROUND: Carcinoma cervix is a common cancer in women worldwide with a high morbidity rate. Radiotherapy is used to treat such tumours. Volumetric Modulated Arc Therapy (VMAT) is considered superior to other techniques with multiple arcs and energies. MATERIALS AND METHODS: Twenty patients with carcinoma cervix underwent radiotherapy in a prospective observation study conducted at our institute...
January 2017: Reports of Practical Oncology and Radiotherapy
https://www.readbyqxmd.com/read/27784990/molecular-targets-in-urothelial-cancer-detection-treatment-and-animal-models-of-bladder-cancer
#15
REVIEW
Dmitriy Smolensky, Kusum Rathore, Maria Cekanova
Bladder cancer remains one of the most expensive cancers to treat in the United States due to the length of required treatment and degree of recurrence. In order to treat bladder cancer more effectively, targeted therapies are being investigated. In order to use targeted therapy in a patient, it is important to provide a genetic background of the patient. Recent advances in genome sequencing, as well as transcriptome analysis, have identified major pathway components altered in bladder cancer. The purpose of this review is to provide a broad background on bladder cancer, including its causes, diagnosis, stages, treatments, animal models, as well as signaling pathways in bladder cancer...
2016: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/27782913/post-therapeutic-dosimetry-of-177lu-dkfz-psma-617-in-the-treatment-of-patients-with-metastatic-castration-resistant-prostate-cancer
#16
Madhav P Yadav, Sanjana Ballal, Madhavi Tripathi, Nishikant A Damle, Ranjit K Sahoo, Amlesh Seth, Chandrasekhar Bal
OBJECTIVE: Lu-DKFZ-PSMA-617, a urea-based compound, binds to the extracellular domain of prostate-specific membrane antigen, thus providing an effective target for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Before its therapeutic use, it is necessary that the radiation dosimetry of this radiopharmaceutical be studied to determine the safe activity that can be administered in patients to prevent haematological, renal and liver toxicity. The present study thus aimed to assess the pharmacokinetics and dosimetry of Lu-DKFZ-PSMA-617 in CRPC patients...
January 2017: Nuclear Medicine Communications
https://www.readbyqxmd.com/read/27776475/multiple-means-by-which-nitric-oxide-can-antagonize-photodynamic-therapy
#17
Albert W Girotti, Jonathan M Fahey, Witold Korytowski
Photodynamic therapy (PDT) is a unique site-specific treatment for eradicating a variety of solid tumors, including prostate, lung, bladder, and brain tumors. PDT is a three-component modality involving (i) administration of a photosensitizing agent (PS), (ii) PS photoexcitation by visible or near-infrared light, and (iii) molecular oxygen. Upon photoexcitation, PS gives rise to tumor-damaging reactive oxygen species, most prominently singlet oxygen (1O2). Previous studies revealed that endogenous nitric oxide (NO) in various mouse tumor models significantly reduced PDT effectiveness...
2016: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/27750007/preclinical-study-on-mitochondria-targeted-photodynamic-therapy-using-a-galactodendritic-chlorin-for-bladder-cancer
#18
Patrícia Manuela Ribeiro Pereira, Sandrina Silva, Mafalda Bispo, Mónica da Rocha Zuzarte, Célia Gomes, Henrique Girão, José A S Cavaleiro, Carlos A Fontes Ribeiro, Joao P C Tome, Rosa Fernandes
Here we report the rational design of a new third-generation photosensitizer (PS), a chlorin conjugated with galactodendritic units, ChlGal8, to improve the effectiveness of bladder cancer treatment. ChlGal8 shows better photo-chemical and -physical properties than a recently reported homologous porphyrin, PorGal8. In addition to inheriting excellent photostability, ability to generate singlet oxygen and to interact with the proteins galectin-1 and human serum albumin (HSA), ChlGal8 exhibits high absorption in the red region of the electromagnetic spectrum...
October 17, 2016: Bioconjugate Chemistry
https://www.readbyqxmd.com/read/27745996/neurovascular-bundle-sparing-radiotherapy-for-prostate-cancer-using-mri-ct-registration-a-dosimetric-feasibility-study
#19
R J Cassidy, X Yang, T Liu, M Thomas, S G Nour, A B Jani
PURPOSE: Sexual dysfunction after radiotherapy for prostate cancer remains an important late adverse toxicity. The neurovascular bundles (NVB) that lie posterolaterally to the prostate are typically spared during prostatectomy, but in traditional radiotherapy planning they are not contoured as an organ-at-risk with dose constraints. Our goal was to determine the dosimetric feasibility of "NVB-sparing" prostate radiotherapy while still delivering adequate dose to the prostate. METHODS: Twenty-five consecutive patients with prostate cancer (with no extraprostatic disease on pelvic magnetic resonance imaging [MRI]) who that were treated with external beam radiotherapy, with the same primary planning target volume margins, to a dose of 79...
October 13, 2016: Medical Dosimetry: Official Journal of the American Association of Medical Dosimetrists
https://www.readbyqxmd.com/read/27743530/targeting-fibroblast-growth-factor-receptors-and-immune-checkpoint-inhibitors-for-the-treatment-of-advanced-bladder-cancer-new-direction-and-new-hope
#20
REVIEW
Rafael Morales-Barrera, Cristina Suárez, Ana Martínez de Castro, Fabricio Racca, Claudia Valverde, Xavier Maldonado, Juan Maria Bastaros, Juan Morote, Joan Carles
Bladder cancer is one of the leading causes of death in Europe and the United States. About 25% of patients with bladder cancer have advanced disease (muscle-invasive or metastatic disease) at presentation and are candidates for systemic chemotherapy. In the setting of metastatic disease, use of cisplatin-based regimens improves survival. However, despite initial high response rates, the responses are typically not durable leading to recurrence and death in the vast majority of these patients with median overall survival of 15months and a 5-year survival rate of ⩽10%...
October 1, 2016: Cancer Treatment Reviews
keyword
keyword
48826
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"